Los Angeles Capital Management’s Prime Medicine PRME Stock Holding History

Los Angeles Capital Management’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$183K	Buy	+52,615	New	+$200K	﹤0.01%	1169

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Los Angeles Capital Management's PRME Position: Q1 2026 in Review

Los Angeles Capital Management opened a new position in Prime Medicine (PRME) in Q1 2026: 52,615 shares worth $183K. The stake represents ﹤0.01% of the portfolio and ranks #1169 among its holdings.

192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

Los Angeles Capital Management held 52,615 shares of Prime Medicine worth $183K as of Q1 2026.
Prime Medicine was a new Los Angeles Capital Management position in Q1 2026.
Prime Medicine made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1169 holding.
192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.